Early diagnosis of Alzheimer’s disease is a primary focus of clinical research, and the identification of biomarkers such as Aβ1-40, Aβ1-42, T-tau, and P-tau has established a robust diagnostic foundation for clinicians. This evidence concerns the gene MAPT and Alzheimer disease.